Abstract
Two patients with chronic-phase chronic granulocytic leukemia initially responded to recombinant interferon α-2a (rIFN-α-2a) but relapsed as a result of development of high-titer neutralizing antibodies to rIFN-α-2a. Both patients were subsequently treated with natural leukocyte IFN-α (IFN-α-n3), and one of the two patients achieved a durable second hematologic and cytogenetic remission. IFN-α-n3 may be considered for patients in whom antibody-mediated resistance to rIFN-α-2a develops.
Original language | English (US) |
---|---|
Pages (from-to) | 231-233 |
Number of pages | 3 |
Journal | American journal of hematology |
Volume | 52 |
Issue number | 3 |
DOIs | |
State | Published - 1996 |
Keywords
- CGL
- Interferon antibodies
- Interferon therapy
ASJC Scopus subject areas
- Hematology